GENPREX INC (GNPX)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$3.50+2.04%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · GNPX
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
A comparable price-assumption read is not available for this company.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Elevated risk of a next-quarter earnings miss: this name is a smaller-cap name (higher miss base rate) and has erratic recent earnings surprises. A fundamental tilt, not a price call.
Model as of 2026-09-04 · Compared with 399 industry peers · Company calendar date is not available
GNPX — legal / regulatory event — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standar…
Dated 2026-08-05
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing . As previously disclosed, on July 29, 2026, the Nasdaq Hearings Panel (the “Panel”) notified Genprex, Inc. (the “Company” or “Genprex”) that the Panel had granted the Company’s request to continue the Company’s listing on The Nasdaq Capital Market (“Nasdaq”) and grant an exception to demonstrate compliance with the $1.00 Minimum Bid Price requirement set forth in Nasdaq Listing Rule 5550(a)(2)…
Why it matters: Following Nasdaq rules is key to keeping the company's stock listed.
Worry ifA press release confirming that Genprex has regained compliance with the $1.00 minimum bid price.
Less concerning ifMore notices of delisting or not meeting Nasdaq rules.
Why it matters: The deal with Roche may help prove biomarkers for Genprex's treatments. Good results can change how the market views them.
Supportive ifLook for news about successful biomarker results from the Roche partnership.
Worry ifBad results or delays in Roche partnership outcomes.
Why it matters: Genprex's listing on Nasdaq is at risk. Compliance is crucial for maintaining investor confidence and access to capital.
Worry ifStock price stays above $1.00 for 10 consecutive trading days.
Less concerning ifStock price stays below $1.00 for 30 straight trading days.
Why it matters: Advancing clinical trials is key for Genprex's growth. Progress could attract more investment.
Supportive ifLook for news on a new trial phase or good results for Reqorsa.
Worry ifWatch for delays or cancellations of planned trials for Reqorsa Gene Therapy.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$341 on $10,000 · ±3.4% | How much price usually moves either way. |
| Bad day | $1,495 loss on $10,000 · 14.9% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $9,963 loss on $10,000 · 99.6% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: High cash burn indicates financial strain. This could impact future operations and growth.
Worry ifOperating cash burn reported above $5 million for Q3.
Less concerning ifCash burn reported below $5 million for Q3.
Why it matters: New patents can strengthen Genprex's market position and protect its innovations. This could attract investors.
Supportive ifNew patents for Reqorsa Gene Therapy have been granted.
Worry ifNo new patents announced. Existing patents are challenged.